Clinical Report: Oral HRS-7535 Lowered A1c in Trial
Overview
Expand on the safety profile to include specific adverse events or tolerability.
Background
Type 2 diabetes management often requires effective glycemic control to prevent complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a key treatment option, but adherence can be challenging due to administration requirements. HRS-7535, a nonpeptide oral GLP-1 RA, offers a promising alternative that does not necessitate fasting, potentially improving patient compliance.
Data Highlights
| Dose (mg) | Mean A1c Reduction (%) | Placebo-Adjusted Reduction (%) | % Achieving A1c < 7.0% |
|---|---|---|---|
| 15 | 1.19 | 0.94 | 49 |
| 30 | 1.59 | 1.34 | 63 |
| 60 | 1.82 | 1.57 | 63 |
| 90 | 1.64 | 1.39 | 60 |
| Placebo | 0.25 | - | 15 |
Key Findings
- HRS-7535 reduced hemoglobin A1c by up to 1.82 percentage points compared to placebo.
- 49% to 63% of patients on HRS-7535 achieved A1c levels below 7.0% versus 15% on placebo.
- Rescue antihyperglycemic therapy was required in only 3% to 8% of patients receiving HRS-7535, compared to 31% in the placebo group.
- Weight reduction was modest, with a maximum of 2.63% in the 90 mg group compared to placebo.
- Changes in fasting plasma glucose and postprandial glucose were significantly greater with HRS-7535 than with placebo.
- The 60 mg dose provided similar efficacy to the 90 mg dose, suggesting potential for dose optimization.
Clinical Implications
The findings suggest that HRS-7535 may be an effective oral treatment option for patients with type 2 diabetes inadequately controlled on metformin. Its non-fasting requirement could enhance adherence, making it a valuable addition to diabetes management strategies.
Conclusion
HRS-7535 demonstrates significant efficacy in lowering A1c levels in type 2 diabetes patients, warranting further investigation in larger trials to confirm its safety and optimal dosing.
Related Resources & Content
- JAMA Network Open, 2023 -- HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial
- The Journal of Clinical Endocrinology & Metabolism — Comparative Analysis of Once-Weekly Insulin Icodec and Daily Insulin Regimens: Efficacy and Hypoglycemia Outcomes Across Demographic Groups
- Clinical Research in Cardiology — Update on Clinical Trials and Registries Discussed at the 2010 American College of Cardiology Congress: Insights from ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE, and Others
- Drugs - Real World Outcomes — Impact of Gliclazide Alone or in Combination with Metformin on Glycemic Management in Indian Patients with Type 2 Diabetes Mellitus: A Retrospective, Longitudinal Analysis Utilizing Electronic Medical Records
- ADA Standards of Care in Diabetes—2026
- HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial | Diabetes and Endocrinology | JAMA Network Open | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
